MAM
Medikabazaar announces R K Narayanan as VP-business partner
Mumbai: Medikabazaar, a B2B medical supplies platform, has announced the appointment of four senior executives to strengthen its leadership team across the country.
R K Narayanan has joined Medikabazaar as the vice president-business partner for its Value Purchase Organization (VPO) business. He will be responsible for supporting the creation of product segments in equipment and devices and expand customer offerings across the VPO business.
Narayanan comes with 30 years of rich experience in expanding the business and has previously worked with Boston Scientific handling upstream marketing & CTO programs. He has had stints with companies like Philips Healthcare, GE Healthcare, and Indchem Electronics.
In a bid to expand its presence, Medikabazaar plans to double its workforce by the end of this financial year in line with its aggressive growth plans, the platform said in a statement.
In another key appointment in the VPO business, Manu Dixit joins Medikabazaar as the business head for the South and West regions. Dixit will be responsible for OEM tie-ups and will address the procurement needs of all medium and small-size hospitals across the region. He has worked with brands such as Johnson & Johnson, GlaxoSmithKline, and Zydus.
The other two business heads who have joined Medikabazaar are Rakesh Gurkha and Chaitanya Sapkal. While Gurkha will be leading the business along with the current Dental Sales team across regions, Sapkal will look into spearheading and expanding the diagnostic business across India.
Gurkha comes with over 22 years of experience in sales and has been associated with companies like Cortex Dental Implant Industries, Acteon, Danaher & the Kavo Group. Sapkal commands over 20 years of experience in handling sales in the West and South regions and has worked with brands like Abbott Healthcare, Johnson & Johnson, Roche Diagnostics, and Trivitron Diagnostics.
“We are thrilled to have this dynamic team join us at such an important juncture in Medikabazaar’s growth journey,” said Medikabazaar CEO & founder Vivek Tiwari. “The new leadership team holds a strong professional track record and cultural connect with the local markets, which I am confident will further help us move strongly towards achieving our mission of ensuring that, people have access to innovative and quality health treatment.”
Brands
Maharashtra panel orders Lodha to refund Rs 5 crore to homebuyers
Consumer court flags unfair practices in long-running property dispute case
MUMBAI: In a sharp rebuke to one of India’s biggest real estate players, the Maharashtra State Consumer Disputes Redressal Commission has directed Macrotech Developers to refund nearly Rs 5 crore to a senior citizen couple, Uttam and Anindita Chatterjee. The ruling, delivered on March 13, 2026, calls out the developer for “deficiency in service” and “unfair trade practices”, bringing closure to a dispute that has stretched over a decade.
The case traces back to 2015, when the couple booked a 3-BHK flat at World Towers in Lower Parel for Rs 12.22 crore, with possession promised within a year. What followed was a series of changes that complicated matters. After deciding to exit the project, they were persuaded to shift to a 4-BHK in another development priced at Rs 8 crore, with delivery scheduled for 2018. However, within months, the price was allegedly increased to Rs 10 crore. After demonetisation reshaped the market, similar flats were reportedly being offered at lower prices, but the couple were not given the benefit.
Despite paying over Rs 2.83 crore, the couple neither received possession nor clarity. Instead, in 2018, the developer unilaterally cancelled the booking, retained part of the amount as earnest money, and argued that the buyers were investors rather than consumers. The commission rejected this claim, observing that casual references to “investment” do not take away consumer rights when the purchase intent is residential.
The bench also held that the developer could not penalise buyers for payment delays while failing to meet its own delivery commitments. It noted the lack of formal documentation for revised terms and termed the prolonged retention of funds without delivering a home as exploitative.
As part of its order, the commission directed the developer to refund Rs 2.83 crore paid by the couple, along with interest at 10 per cent per annum, amounting to around Rs 2.12 crore. In addition, Rs 1 lakh has been awarded for mental agony and Rs 50,000 towards litigation costs, taking the total payout to over Rs 5 crore. The developer has been asked to comply within two months.
For now, the ruling serves as a reminder that in real estate, shifting terms and delayed promises can carry a significant cost.
